Exelixis: Q3 Earnings Snapshot

Exelixis Inc. (EXEL) reported Q3 profit of $218.1M, or 85 cents per share, beating analyst estimates of 89 cents. Revenue was $658.7M, exceeding forecasts of $653.1M. The company expects full-year revenue of $2.5B to $2.55B.

Original reporting
Published Oct 29, 2026, 8:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 8:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Exelixis: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$EXELBullishMed
01

Why it matters

For traders, the key decision inputs are the magnitude of the EPS and revenue beats versus estimates and whether the FY revenue range meaningfully changes the forward revenue trajectory.

02

Market read

Q3 beat plus a defined FY revenue range is a direct earnings-model update catalyst for EXEL.

03

What to watch

The article does not include pipeline updates, trial readouts, or cash-flow details, which can dominate valuation changes for biotech beyond headline EPS and revenue.

Relevance 8/10Novelty 8/10Timing: reported Thursday after the quarter closed, before/around the next trading session

Background

The piece is an AP earnings snapshot generated from Zacks data, summarizing Q3 results versus analyst expectations and providing full-year revenue guidance.

Company-level read

Ticker impact

$EXELBullishMedium confidence
Context

Exelixis reported Q3 profit of $218.1M, EPS 85 cents (94 cents adjusted), revenue $658.7M, and guided FY revenue to $2.5B-$2.55B.

Expected impact

Likely upward bias as traders price in the beat and the guided FY revenue range.

Evidence & confidence

The article provides both the quarter’s beat versus estimates and a concrete FY revenue outlook, which are direct inputs to earnings-model updates and positioning.

Market effects

Biopharma earnings prints can shift sentiment around small-to-mid cap oncology drug developers, but this is company-specific rather than a sector-wide catalyst.

Limited regional impact; the news is US-listed company earnings.

Low global spillover beyond oncology/biopharma investor sentiment.

Counterpoint

If the FY revenue range is only modestly above consensus, the initial reaction could fade despite the Q3 beat.

Key entities

  • Exelixis Inc.

    US-listed biopharmaceutical company reporting Q3 results and full-year revenue guidance.

  • Zacks Investment Research

    Analyst estimate provider cited for consensus EPS and revenue expectations.

Related articles

$EXELMedAI 8/10

Exelixis (EXEL) Q3 2026 Earnings Call Transcript

Exelixis reported Q3 2026 revenues of $659M, with cabozantinib franchise U.S. net product revenues at $605M, up 11% YoY. Global revenues reached $818M. Zanzalintinib is a key growth driver, with multiple trials advancing. GAAP net income was $218M ($0.88 per share). The company updated full-year guidance and repurchased $250M in stock.

$EXELMed

Exelixis Inc (EXEL) (Q3 2026) Earnings Call Highlights: CABOMETYX Momentum

Exelixis Inc (EXEL) reported Q3 2026 earnings, highlighting delays in zanzalintinib's PDUFA date to March 2027 and STELLAR-304 results to Q1 2027. Full-year 2026 revenue guidance was maintained but reflects reduced expectations due to temporal NET indication revenue. CABOMETYX sales grew 6% quarter-over-quarter, with gross-to-net deductions projected at 30%. The company addressed competition, clinical trials, and the 340B program's minimal impact.

$EXELMed

BMO raises Exelixis stock price target to $60 on OpEx outlook

BMO Capital raised Exelixis' (NASDAQ:EXEL) price target to $60 from $54, citing adjusted long-term operating expense assumptions. The stock trades near its 52-week high at $66.20, up 70% over the past year. Exelixis reported Q3 2026 earnings of $0.94 per share, beating estimates by 8.05%, with revenue of $658.69 million, a 1.81% beat. The company maintained its 2026 revenue guidance, attributing it to the gradual ramp of its NET product.